Ginkgo Bioworks Holdings, Inc.
DNA
$8.03
$0.030.38%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.84M | 49.60M | 48.32M | 43.85M | 89.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.84M | 49.60M | 48.32M | 43.85M | 89.05M |
| Cost of Revenue | 12.80M | 14.82M | 12.05M | 9.62M | 12.00M |
| Gross Profit | 26.04M | 34.78M | 36.27M | 34.23M | 77.04M |
| SG&A Expenses | 44.95M | 43.28M | 49.04M | 51.99M | 52.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 127.11M | 111.47M | 132.01M | 137.98M | 141.30M |
| Operating Income | -88.27M | -61.87M | -83.70M | -94.14M | -52.26M |
| Income Before Tax | -80.75M | -60.58M | -90.87M | -107.86M | -56.78M |
| Income Tax Expenses | 1.00K | -283.00K | 88.00K | -325.00K | -375.00K |
| Earnings from Continuing Operations | -80.76M | -60.30M | -90.96M | -107.53M | -56.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.76M | -60.30M | -90.96M | -107.53M | -56.40M |
| EBIT | -88.27M | -61.87M | -83.70M | -94.14M | -52.26M |
| EBITDA | -74.10M | -46.07M | -68.33M | -78.49M | -35.09M |
| EPS Basic | -1.45 | -1.10 | -1.68 | -2.00 | -1.08 |
| Normalized Basic EPS | -0.93 | -0.65 | -0.94 | -1.00 | -0.48 |
| EPS Diluted | -1.45 | -1.10 | -1.68 | -2.00 | -1.08 |
| Normalized Diluted EPS | -0.93 | -0.65 | -0.94 | -1.00 | -0.48 |
| Average Basic Shares Outstanding | 55.63M | 54.86M | 54.24M | 53.81M | 52.24M |
| Average Diluted Shares Outstanding | 55.63M | 54.86M | 54.24M | 53.81M | 52.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |